These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38879876)

  • 1. Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo.
    Agner ML; Parraga SP; Arkhipenko ZM; Pichardo RO; McMichael AJ; Feldman SR
    Expert Rev Clin Immunol; 2024 Jul; 20(7):695-702. PubMed ID: 38879876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
    Rosmarin D; Passeron T; Pandya AG; Grimes P; Harris JE; Desai SR; Lebwohl M; Ruer-Mulard M; Seneschal J; Wolkerstorfer A; Kornacki D; Sun K; Butler K; Ezzedine K;
    N Engl J Med; 2022 Oct; 387(16):1445-1455. PubMed ID: 36260792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
    Kang C
    Drugs; 2024 May; 84(5):579-586. PubMed ID: 38625661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta-analysis of therapeutic trials of topical ruxolitinib cream for the treatment of vitiligo: therapeutic efficacy, safety, and implications for therapeutic practice.
    Hussein AFA; Shams AS; Hosny N; Elrosasy A; Kobtan M; Shafik YA; Alnatsheh ZR; Zeid MA; Qarma M; Ibrahim YK; Al-Sultany HA
    Arch Dermatol Res; 2024 Aug; 316(8):518. PubMed ID: 39134884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo.
    Grossmann MC; Haidari W; Feldman SR
    J Drugs Dermatol; 2023 Jul; 22(7):664-667. PubMed ID: 37410047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
    Rosmarin D; Pandya AG; Lebwohl M; Grimes P; Hamzavi I; Gottlieb AB; Butler K; Kuo F; Sun K; Ji T; Howell MD; Harris JE
    Lancet; 2020 Jul; 396(10244):110-120. PubMed ID: 32653055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of Ruxolitinib for Treatment of Non-Segmental Vitiligo.
    Hwang JR; Driscoll MS
    Ann Pharmacother; 2023 Aug; 57(8):948-955. PubMed ID: 36564903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical ruxolitinib: A new treatment for vitiligo.
    Tavoletti G; Avallone G; Conforti C; Roccuzzo G; Maronese CA; Mattioli MA; Quaglino P; Zalaudek I; Marzano AV; Ribero S; Alberti-Violetti S
    J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2222-2230. PubMed ID: 37147856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis.
    Yuan Y; Zhang Y; Zheng L; Gu X; Yu S; Sun X
    Syst Rev; 2024 Oct; 13(1):250. PubMed ID: 39358803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychometric Evaluation of the Facial and Total Vitiligo Area Scoring Index Instruments in the TRuE-V Phase 3 Studies.
    Bibeau K; Butler K; Wang M; Skaltsa K; Hamzavi IH
    Dermatol Ther (Heidelb); 2024 Aug; 14(8):2223-2234. PubMed ID: 39078582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
    Liu LY; Strassner JP; Refat MA; Harris JE; King BA
    J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib.
    Rothstein B; Joshipura D; Saraiya A; Abdat R; Ashkar H; Turkowski Y; Sheth V; Huang V; Au SC; Kachuk C; Dumont N; Gottlieb AB; Rosmarin D
    J Am Acad Dermatol; 2017 Jun; 76(6):1054-1060.e1. PubMed ID: 28390737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year.
    Hu W; Thornton M; Livingston RA
    Am J Clin Dermatol; 2024 Mar; 25(2):327-332. PubMed ID: 38243107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
    Goker Bagca B; Biray Avci C
    Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.
    Gong X; Chen X; Kuligowski ME; Liu X; Liu X; Cimino E; McGee R; Yeleswaram S
    Am J Clin Dermatol; 2021 Jul; 22(4):555-566. PubMed ID: 33982267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review.
    Utama A; Wijesinghe R; Thng S
    Int J Dermatol; 2024 Aug; 63(8):1020-1035. PubMed ID: 38610078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protocol for a systematic review and meta-analysis on Janus kinase inhibitors in the management of vitiligo.
    Pranić S; Pulumati A; Vuković D
    Syst Rev; 2024 Apr; 13(1):110. PubMed ID: 38641831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA).
    Harris JE; Rashighi M; Nguyen N; Jabbari A; Ulerio G; Clynes R; Christiano AM; Mackay-Wiggan J
    J Am Acad Dermatol; 2016 Feb; 74(2):370-1. PubMed ID: 26685721
    [No Abstract]   [Full Text] [Related]  

  • 19. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.
    Phan K; Phan S; Shumack S; Gupta M
    J Dermatolog Treat; 2022 Feb; 33(1):173-177. PubMed ID: 32096671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Clinical Applications of Topical Ruxolitinib: A Case Series.
    Zundell MP; Al-Dehneem R; Song T; Yousif J; Gottlieb AB
    J Drugs Dermatol; 2024 Mar; 23(3):188-190. PubMed ID: 38443119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.